| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC23900 | AICAR phosphate Featured | AICAR phosphate (Acadesine, AICA Riboside, NSC 105823) is a selective AMPK activator in both hepatocytes and adipocytes. |
|
| DC9330 | AIM-100 Featured | AIM-100 is a small molecule inhibitor of Ack1 with an IC50 of 24 nM IC50 value: 24 nM [3] Target: Ack1 Ack1 inhibitor AIM-100 not only inhibited Ack1 activation but also suppressed AKT tyrosine phosphorylation, leading to cell cycle arrest in the G1 ph |
|
| DC12402 | AJM300 | AJM300 (AJM 300, AJM-300) is a novel potent, selective, oraaly available alpha 4 integrin antagonist fortreatment of active ulcerative colitis.. |
|
| DC23660 | AK106-001616(AK 106-001616) | AK106-001616 (AK 106-001616) is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) with IC50 of 3.8 nM (human cPLA2 enzyme). |
|
| DC21991 | AK306 | AK306 is a small molecule clathrin heavy chain (CLTC/CHC) binding compound that induces arrest and apoptosis of the HCT116 colon cancer cell line with EC50 of 50 nM. |
|
| DC7540 | SIRT2 Inhibitor II, AK-7 Featured | AK-7 is a cell- and brain-permeable inhibitor of SIRT2 (IC50 = 15.5 μM). |
|
| DC23789 | AK778 Featured | AK778 (Col001) is a small-molecule compound that inhibits the interaction of Hsp47 with collagen, competitively inhibits the interaction and causes the inhibition of collagen secretion by destabilizing the collagen triple helix. . |
|
| DC20649 | AKB-9778 Featured | AKB-9778 is a potent, selective inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP) with IC50 of 17 pM. |
|
| DC12158 | AKOS B018304 Featured | AKOS B018304 is an arylalkylidene derivative, with polar substitution at para-position. |
|
| DC10941 | AKR1C3 inhibitor KV-37 | AKR1C3 inhibitor KV-37 is a potent, isoform selective and metabolically stable inhibitor of Aldo-keto reductase 1C3 (AKR1C3) with IC50 of 66 nM, displays 109-fold selectivity over AKR1C2. |
|
| DC8458 | Akt Inhibitor VIII Featured | Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity (IC50 = 58 nM, 210 nM, and 2.12 μM; respectively). |
|
| DC8695 | Akt1 and Akt2-IN-1 | Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity. |
|
| DC9677 | AL 082D06(D-06) Featured | AL 082D06(D-06) is the first selective, nonsteroidal glucocorticoid receptor (GR) antagonist with Ki of 210 nM, exhibits excellent selectivity against AR, PR, MR and ER(Ki > 10 uM). |
|
| DC20260 | AL-335 Featured | AL-335 is a potent inhibitor of hepatitis C virus (HCV) NS5B polymerase with IE50 values as low as 70 nM. AL-335 is potentially useful for the Treatment of Hepatitis C Infection. AL-335 demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. AL-335 was selected for the clinical development where it showed promising results in phase 1 and 2 trials. |
|
| DC21111 | AL-9 | AL-9 is a small molecule HCV replication inhibitor with EC50 of 0.29 and 0.75 uM for genotype 1b and 2a, inhibits purified PI4KIIIα with IC50 of 0.57 uM. |
|
| DC20652 | ALB-127158 | ALB-127158 is a potent (IC50=7 nM), selective, non-peptide antagonist of MCHR1 (Melanin-concentrating hormone receptor 1) for treatment of obesity.. |
|
| DC10780 | ALB-127158(a) Featured | ALB-127158A, also known as ALB-127158(a), is a MCH1 antagonist for the treatment of obesity. |
|
| DCAPI1243 | Albendazole(Albenza) | Albendazole(Albenza) |
|
| DC20174 | Albiglutide Featured | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist). |
|
| DCAPI1467 | Alcaftadine | Alcaftadine |
|
| DC8723 | Alda-1 Featured | Alda-1 is an ALDH2 agonist, cell-permeable activator of both the wild-type ALDH2*1 and the asian E487K mutant ALDH2*2 forms of mitochondrial aldehyde dehydrogenase 2 (mtALDH2). |
|
| DC21993 | ALDH1A inhibitor 673A | ALDH1A inhibitor 673A (ALDH1Ai 673A) is a potent, selective, pan-ALDH1A inhibitor with IC50 of 246, 230 and 348 nM for ALDH1A1, ALDH1A2 and ALDH1A3, respectively. |
|
| DC11024 | ALDH3A1 inhibitor EN40 | ALDH3A1 inhibitor EN40 is a potent and selective, covalent, in vivo-active inhibitor of ALDH3A1 with IC50 of 2 uM, demonstrates no activity against ALDH1A3 and ALDH6A1 at 30 uM. |
|
| DC20653 | ALE-0540 Featured | ALE-0540 is a nerve growth factor (NGF) antagonist that inhibits the binding of NGF to TrkA or both p75 and TrkA with IC50 of 5.88 and 3.72 uM, respectively. |
|
| DCAPI1034 | Alendronate (Fosamax) | Alendronate (Fosamax) |
|
| DC22492 | Alexamorelin Featured | Alexamorelin is a synthetic growth hormone (GH) secretagogue. |
|
| DC12389 | Alflutinib Featured | Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.The Alflutinib free base form is not stable, so we make it the mesylate s |
|
| DC12072 | Alflutinib (AST2818 mesylate) Featured | Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.. |
|
| DC9334 | Alfuzosin | Alfuzosin is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH). |
|
| DC22211 | ALG1001 (Risuteganib) Featured | ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis; ALG1001 inhibits an integrin-mediated pathway of the vitreoretinal interface, connecting the posterior aspect of the vitreous with the internal limiting membrane of the retina. In blocking this pathway, ALG-1001 helps to achieve vitreous breakdown and separation from the retina. |
|
